Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer - NeoPHOEBE Meeting Abstract
| Authors: | Loibl, S.; de la Pena, L.; Nekljudova, V.; Zardavas, D.; Michiels, S.; Denkert, C.; Rezai, M.; Bermejo, B.; Lee, S. C.; Turri, S.; Urban, P.; Kummel, S.; Lux, M.; Piccart, M.; von Minckwitz, G.; Baselga, J.; Loi, S. |
| Abstract Title: | Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer - NeoPHOEBE |
| Meeting Title: | 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 76 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2015 Dec 8-12 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2016-02-15 |
| Language: | English |
| ACCESSION: | WOS:000375622400320 |
| DOI: | 10.1158/1538-7445.sabcs15-p1-14-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P1-14-01 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work